leisure time -WSS

leisure time

author：knowledge 2025-09-29 22:53:55 - browse：7

illustration of one blue dna strand — Adobe

The Food and Drug Administration is convening a meeting of outside experts on Tuesday to review exa-cel, a CRISPR-based treatment for sickle cell disease made by Vertex Pharmaceuticals and CRISPR Therapeutics.

Tuesday’s meeting is set up a bit differently than most FDA advisory panels. The agency has not raised any concerns about exa-cel’s efficacy or safety, and there will not be a typical vote at the end of the day on whether the data from exa-cel’s pivotal clinical trial support an approval as a treatment for sickle cell disease.

Instead, the FDA is seeking input about the methods used by Vertex and CRISPR Therapeutics to evaluate the risk of inadvertently making unwanted changes to patients’ DNA — so-called off-target editing — when exa-cel is administered.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： Welsh Carson private equity firm escapes from FTC antitrust case

WSS

With competition flaring, obesity drug hits goal in liver disease study

A solution to the after

Most antidepressants don't work on kids, teens, study finds

GSK’s asthma push continues as drug succeeds in Phase 3 trials

Chemotherapy before breast cancer surgery might fuel metastasis

Dario to buy mental health app maker Twill in cash and stock deal

explore

leisure time

hotspot

What does generative AI mean for health care? We asked experts

How a small hospital in rural Puerto Rico survived Hurricane Maria

Novavax promises a turnaround & Lilly roils the obesity market

Antivenom research: Lessons from HIV applied in search for universal antidote

Psychedelics group wrestles with new pharma identity

As health system earnings go up, health insurance stocks go down

Heart attack and stroke risk calculators need revising

A new nitrogen execution bill also undermines medical licensing

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

As health system earnings go up, health insurance stocks go down

entertainment

Sepsis can kill a child within hours. Here's how hospitals are fighting back

Has Bernie Sanders reached the limit of his pharma bullying effort?

New documents shed light on MD Anderson Cancer Institute feud

Obesity drugs seen as possible treatment for liver disease MASH

The Harvard botanist who searched for psychedelics in the Amazon

Community Health Systems hospitals under DOJ investigation

focus

focus

Wikipedia

explore